The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem BrainsSaia-Cereda V.M.a · Santana A.G.a · Schmitt A.b, c · Falkai P.b · Martins-de-Souza D.a, d
aLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil; bDepartment of Psychiatry and Psychotherapy, Ludwig Maximilian University (LMU), Munich, Germany; cLaboratory of Neurosciences (LIM-27), Institute of Psychiatry, University of São Paulo, São Paulo, and dUNICAMP's Neurobiology Center, Campinas, Brazil
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Schizophrenia (SCZ) is a serious neuropsychiatric disorder that manifests through several symptoms from early adulthood. Numerous studies over the last decades have led to significant advances in increasing our understanding of the factors involved in SCZ. For example, mass spectrometry-based proteomic analysis has provided important insights by uncovering protein dysfunctions inherent to SCZ. Here, we present a comprehensive analysis of the nuclear proteome of postmortem brain tissues from corpus callosum (CC) and anterior temporal lobe (ATL). We show an overview of the role of deregulated nuclear proteins in these two main regions of the brain: the first, mostly composed of glial cells and axons of neurons, and the second, represented mainly by neuronal cell bodies. These samples were collected from SCZ patients in an attempt to characterize the role of the nucleus in the disease process. With the ATL nucleus enrichment, we found 224 proteins present at different levels, and 76 of these were nuclear proteins. In the CC analysis, we identified 119 present at different levels, and 24 of these were nuclear proteins. The differentially expressed nuclear proteins of ATL are mainly associated with the spliceosome, whereas those of the CC region are associated with calcium/calmodulin signaling.
© 2017 S. Karger AG, Basel
- Kahn RS, Sommer IE, Murray RM, et al: Schizophrenia. Nat Rev Dis Primers 2015;1:15067.
- Owen MJ, Sawa A, Mortensen PB: Schizophrenia Lancet 2016;388:86-97.
- Schulz SC, Murray A: Assessing cognitive impairment in patients with schizophrenia. J Clin Psychiatry 2016;77:3-7.
Sadock BJ, Sadock VA: Compêndio de Psiquiatria: Ciência do Comportamento e Psiquiatria Clínica, Artmed. Artmed, Porto Alegre, 2007.
- Nascimento JM, Martins-de-Souza D: The proteome of schizophrenia. NPJ Schizophr 2015;1:14003.
- Martins-de-Souza D, Guest PC, Rahmoune H, Bahn S: Proteomic approaches to unravel the complexity of schizophrenia. Expert Rev Proteomics 2012;9:97-108.
- Bradshaw RA, Burlingame AL: From proteins to proteomics. IUBMB Life 2005;57:267-272.
- Taylor SW, Fahy E, Ghosh SS: Global organellar proteomics. Trends Biotechnol 2003;21:82-88.
Alberts B, Johnson A, Lewis J, et al: Molecular Biology of the Cell. New York, Garland Science, 2002, vol 4, pp 191-234.
- Narula K, Datta A, Chakraborty N, Chakraborty S: Comparative analyses of nuclear proteome: extending its function. Front Plant Sci 2013;4:100.
- Harrison PJ: Using our brains: the findings, flaws, and future of postmortem studies of psychiatric disorders. Biol Psychiatry 2011;69:102-103.
- Guo H, Christoff J, Campos V, Li Y: Normal corpus callosum in Emx1 mutant mice with C57BL/6 background. Biochemical and biophysical research communications. Biochem Biophys Res Commun 2000;276:649-653.
- Rotarska-Jagiela A, Schönmeyer R, Oertel V, et al: The corpus callosum in schizophrenia-volume and connectivity changes affect specific regions. Neuroimage 2008;39:1522-1532.
- Innocenti GM, Ansermet F, Parnas J: Schizophrenia, neurodevelopment and corpus callosum. Mol Psychiatry 2003;8:261-274.
- Cox B, Emili A: Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc 2006;1:1872-1878.
- Maccarrone G, Rewerts C, Lebar M, et al: Proteome profiling of peripheral mononuclear cells from human blood. Proteomics 2013;13:893-897.
Purves D, Augustine GJ, David F, et al: Neuroscience. Sunderland, Sinauer Associates, 2008, vol 4, pp 15-16.
- Fitsiori A, Nguyen D, Karentzos A, et al: The corpus callosum: white matter or terra incognita. Br J Radiol 2011;84:5-18.
- Liu X, Liu PCC, Santoro N, Thiele DJ: Conservation of a stress response: human heat shock transcription factors functionally substitute for yeast HSF. EMBO J 1997;16:6466-6477.
- Voellmy R, et al: Chaperone regulation of the heat shock protein response. Adv Exp Med Biol 2007;594:89-99.
- Shamovsky I, Ivannikov M, Kandel ES, et al: RNA-mediated response to heat shock in mammalian cells. Nature 2006;440:4-8.
- Anckar J, Sistonen L: Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu Rev Biochem 2011;80:1089-1115.
- Kultz D: Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol 2005;67:225-257.
- Sarge KD, Murphy SP, Morimoto RI: Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol 1993;13:1392-1407.
- Baler R, Dahl G, Voellmyl R: Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Mol Cell Biol 1993;13:2486-2496.
- Zuo J, Rungger D: Multiple layers of regulation of human heat shock transcription factor 1. Mol Cell Biol 1995;15:4319-4330.
- Cotto J, Kline M, Morimoto RI: Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation. J Biol Chem 1996;271:3355-3359.
- Zou J, Guo Y, Guettouche T, et al: Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94:471-480.
- Knauf U, Newton EM, Kyriakis J, Kingston RE: Repression of human heat shock factor 1 activity at control temperature by phosphorylation. Genes Dev 1996;10:2782-2793.
- Kline MP, Morimoto RI: Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation. Mol Cell Biol 1997;17:2107-2115.
- Guettouche T, Boellmann F, Lane WS, Voellmy R: Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem 2005;14:1-14.
- Kim JJ, Mandelli L, Lim S, et al: Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008;258:239-244.
- Kowalczyk M, Owczarek A, Suchanek R: Heat shock protein 70 gene polymorphisms are associated with paranoid schizophrenia in the Polish population. Cell Stress Chaperones 2014;19:205-215.
- Arion D, Unger T, Lewis DA, et al: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007;2:711-721.
- Bano D, Piazzesi A, Salomoni P, Nicotera P: The histone variant H3.3 claims its place in the crowded scene of epigenetics. Aging 2017;9:602-614.
- Martins-De-Souza D, Dias-Neto E, Schmitt A, et al: Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry 2010;11:110-120.
- Beck HC: Mass spectrometry in epigenetic research. Methods Mol Biol 2010;593:263-282.
- Ibi D: Epigenetic signaling in schizophrenia. Cell Signal 2016;27:2131-2136.
- Chase KA, Gavin D, Guidotti A, Sharma R: Histone methylation at H3K9; evidence for a restrictive epigenome in schizophrenia. Schizophr Res 2014;149:15-20.
- Gavin D, Sharma RP: Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 2011;34:882-888.
- Hasan A, Mitchell A: Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci 2013;263:273-284.
- Will CL, Luhrmann R: Spliceosome structure and function. Cold Spring Harb Perspect Biol 2011;3:1-24.
- Ward AJ, Cooper TA: The pathobiology of splicing. J Pathol 2011;220:152-163.
- Cassoli JS, Iwata K, Steiner J, et al: Effect of MK-801 and clozapine on the proteome of cultured human oligodendrocytes. Front Cell Neurosci 2016;10:1-14.
- Zhao L, Mandler MD, Yi H, Feng Y: Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein. Proc Natl Acad Sci USA 2010;107:19061-19066.
- Iwata K, Matsuzaki H, Manabe T, Mori N: Altering the expression balance of hnRNP C1 and C2 changes the expression of myelination-related genes. Psychiatry Res 2011;190:364-366.
- Saia-Cereda VM, Cassoli JS, Schmitt A, et al: Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. Eur Arch Psychiatry Clin Neurosci 2015;265:601-612.
- Cassoli JS, Guest PC, Malchow B, et al: Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophr 2015;1:15034.
- Davalieva K, Kostovska IM, Dwork AJ: Proteomics research in schizophrenia. Front Cell Neurosci 2016;10:1-22.
- Lin CL, Bristol LA, Jin L, et al: Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602.
- Huntsman M, Tran B-V, Potkin SG Jr, et al: Altered ratios of alternatively spliced long and short γ2 subunit mRNAs of the γ-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proc Natl Acad Sci USA 1998;95:15066-15071.
- D'Souza I, Poorkaj PP, Hong M, et al: Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA 1999;96:5598-5603.
- Park E, Iaccarino C, Lee J, et al: Regulatory roles of heterogeneous nuclear ribonucleoprotein M and Nova-1 protein in alternative splicing of dopamine D2 receptor Pre-mRNA. J Biol Chem 2011;286:25301-25308.
- Meltzer HY, Stahl SM: The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976;2:19-76.
- Naz H, Islam A, Ahmad F, Hassan I: Calcium/calmodulin-dependent protein kinase IV: a multifunctional enzyme and potential therapeutic target. Prog Biophys Mol Biol 2016;121:54-65.
Jimerson D, Post R, Carman J, et al: CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 1979;14:37-51.
- Lidow MS: Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res Rev 2003;43:70-84.
- Vendrell M, Aliguk R, Bachs O, Serratosa J: Presence of calmodulin and calmodulin-binding proteins in the nuclei of brain cells. J Neurochem 1991;57:622-628.
- Szabo M, Dulka K, Gulya K: Calmodulin inhibition regulates morphological and functional changes related to the actin cytoskeleton in pure microglial cells. Brain Res Bull 2015;120:41-50.
- Underhill SM, Wheeler XDS, Amara SG: Differential regulation of two isoforms of the glial glutamate transporter EAAT2 by DLG1 and CaMKII. J Neurosci 2015;35:5260-5270.
- Gadea A, Lo E, Herna A, Marı A: Role of Ca2+ and calmodulin-dependent enzymes in the regulation of glycine transport in Muller glia. J Neurochem 2002;80:634-645.
- Perez-Garcia JM, Valentin C, et al: Glial cell line-derived neurotrophic factor increases intracellular calcium concentration. Role of calcium/calmodulin in the activation of the phosphatidylinositol 3-kinase pathway. J Biol Chem 2004;279:6132-6142.
- Saia-Cereda VM, Cassoli JS, Schmitt A, et al: Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. Schizophr Res 2016;177:70-77.
- Toyooka K, Asama K, Watanabe Y, Muratake T: Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002;110:249-257.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.